What is Visual Snow?

Visual Snow is a condition that appears similar to static on a television set, appearing across the entire visual field. Learn more ...

What are Floaters?

Floaters are a condition characterized by the appearance of specks, or spots appearing either intermittently, or constantly across the visual field. Learn more ...

What is Macular Degeneration?

Macular Degeneration is a visual disturbance that can result in loss of central vision, which often entails inability to see fine details, to read, or to recognize faces. Learn more ...

Donate Today

We need you to help save the eyesight of millions of people. The Eye on Vision Foundation accepts all donations, no matter how big or small. Every dollar makes a difference!

 

 

 

 

 

 

Frost & Sullivan Lauds MacuCLEAR's Development of a Potentially Blockbuster Drug for Dry Age-Related Macular Degeneration

MacuCLEAR focuses on improving the blood flow in dry AMD patients

 

MOUNTAIN VIEW, Calif. - Oct. 3, 2011 - Based on its recent analysis of the retinal diseases market, Frost & Sullivan recognizes MacuCLEAR, Inc. with the 2011 North American Frost & Sullivan Award for New Product Innovation for its flagship drug, MC-1101. This drug treats very early stages of dry age-related macular degeneration (AMD) before it can progress to wet AMD and eventually, blindness.

When people age, the blood flow to the eye reduces, resulting in a build-up of waste, particularly in the Bruch's membrane. This thickening of the membrane causes it to rupture. When the body tries to form new vessels to compensate for the reduced blood flow, they too will breakdown and bleed in the retina when the Bruch's membrane ruptures.

MacuCLEAR's MC-1101 has the ability to restore blood flow by causing vasodilation of the choroid vessels, removing the accumulated waste, and delivering anti-inflammatory and anti-oxidative effects. An analysis of the choroidal blood data suggests that MC-1101 may reach the back of the eye at the macular area to improve choroidal blood circulation following topical ocular instillation.

"Unlike the currently available AMD treatments that are injected into the eyeball, MC-1011 is a topical drug," said Frost & Sullivan Industry Manager Jennifer Brice. "MacuCLEAR has evaluated several novel eye drop delivery systems to facilitate the most effective delivery of MC-1101."

MacuCLEAR has had a collaborative business relationship with Mystic Pharmaceuticals, Inc. to combine MC-1011 with its novel VersiDoser? delivery system. Standard eyedroppers often deliver too large drops into the eye causing product waste and compliance issues, especially with the elderly population. The VersiDoser? delivery system, however, consists of individually packaged drops which can be precisely sized and accurately delivered with a unique dispenser that makes it a safe, effective, and easier way to deliver ophthalmic medicine versus traditional eyedroppers. The choice of which novel delivery system will primarily depend on MacuCLEAR's strategic marketing partner.

Due to the high unmet need and lack of treatments for dry AMD, MacuCLEAR has been granted Fast Track status by the Food and Drug Administration (FDA). Going through the abbreviated approval pathway will require less data collection, lower cost of production, reduced time for approval and, ultimately, diminished prices for consumers.

MacuCLEAR's team has a combined experience of more than 75 years in the development and commercialization of life science technologies. The dry AMD market has a potential of more than $5 billion, especially with the rise in population of the elderly and a doubling of AMD cases by 2050.

So far, MacuCLEAR is unique in its focus on increasing the blood flow in dry AMD patients. Its competitors are working on uncovering the potential causes of cellular debris and none of them have been able to progress past Phase II for the treatment of dry AMD.

"MacuCLEAR's MC-1101 has already completed Phase Ib, a Proof of Concept human trial," said Brice. "The results of the study demonstrated that MC-1011 is safe with a low incidence of treatment-emergent adverse events that were generally mild in severity."

MacuCLEAR is ready to initiate Phase 3a efficacy trial. Upon successful conclusion of this trial, the company expects to secure a strategic partnership with a big pharma company to complete a 3b study and bring this drug to market.

Each year, Frost & Sullivan presents this award to the company that demonstrates innovation in developing a product. The recipient leverages leading edge technologies to offer value-added features while increasing the ROI for customers. In turn, the innovation enables the company to acquire new customers and increase their market penetration.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About MacuCLEAR, Inc.

MacuCLEAR, Inc. is a specialty pharmaceutical company focused on the discovery and development of novel solutions for the treatment of vascular disorders of the eye. MacuCLEAR's lead product is MC-1101 for the treatment of dry AMD. MC-1101 has successfully completed a Phase Ib/Proof of Concept human clinical trial.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.awards.frost.com.

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

http://www.frost.com/prod/servlet/press-release-print.pag?docid=243660073&ctxixpLabel=FcmCtx4


 
Vote on Facebook for Eye on Vision to Earn Money for the Foundation

The company Geekatoo is running a contest through the end of August and giving away profits to charity! The Eye on Vision Foundation is currently in the lead! Please vote today to keep us up at the top!

(1) Simply go here:?? http://www.facebook.com/geekatoo?sk=app_190322544333196

(2) Then like Geekatoo.

(3) Click on the "Click here to see the results chose from a list" button and select the Eye on Vision Foundation.?


 
New Patient Account
My name is Danielle, and I have had VS for as long as I can remember. I am 24 now, but I can recall seeing the snow when I was very little. I thought it meant I was still tired, so I would sleep all day, but still see the spots.? I thought everyone saw them, until I told my mom about them one day and she took me to see an ophthalmologist.? They did some tests on me, but couldn't see anything wrong, and basically told me I was making it up. After that, I just learned to live with it and I never really told anyone about it. This January, I had LASIK surgery to correct my vision. It worked wonderfully, except there is a drastic increase in my VS, especially at night. It was always the worst at night, but now it's to the point where I have to feel my way along the walls because the snow just overtakes everything. The VS is much worse on solid backgrounds (sky, walls). The VS is there 24/7, eyes open or closed, it just never goes away. I would love to see for 2 seconds without these spots in front of my eyes, I can't even imagine how clear things would look.?
I went to see a retinal specialist the other day, and she determined there is nothing wrong with my eyes, but is sending me for an ERG to see if something is wrong with the way my eyes and brain interact.?

Yesterday I had two ERGs done where it was determined that there is nothing wrong with my eyes, nor the way in which my eyes and brain send messages to one another. I feel like I keep hitting dead end after dead end, and the doctors don't really believe me. I feel as though I am being tested for all the wrong things, because they doctors have NO CLUE what I am trying to describe to them. I am sick of going to Dr.'s that have never even heard of visual snow. It clearly exists, if we all share the same symptoms. I honestly feel as though it isn't life threatening, and also that I will never be cured, but I don't want to give up! I want to know WHY we have to live with this.

 
GoodSearch Giveaway
Take a minute to help us win $1,000!? Download the Eye On Vision Foundation Corp - EOVF toolbar and every time you shop at one of more than 1,500 participating stores, a percentage of your purchase will automatically go to our cause! The five organizations that have the most toolbars downloaded in October win an extra $1,000 each so please add it and share with friends today!! http://www.goodsearch.com/toolbar/eye-on-vision-foundation-corp-eovf.

 
Personal Story from a Sufferer of VS, PMA and Floaters

I grew up in the South Florida area. Currently live in Atlanta practicing Architecture.
I have had visual snow for about 41 years, having VS continuously since I was 17 or so. At that adolescent age with typical coping difficulties and the prevailing VS symptoms, no doctor knew anything about, I felt very isolated and wound up in a psychologist?s office. Surely my parents and the psychologist thought it was 100% emotional. In addition, at that time I had a lot of tests EKG, neurologist., ophthalmologist and the like. All normal.

Late last year, I lost my job and have been going through a tougher than normal time. I returned a therapist for some good ol? counseling which has helped tremendously. What has become noticeable and at times bothersome is the VS. I was given Paxil and Seroquel XR at night to help with job loss- related depression.
I don?t know if during this recent time the VS has really become more intense, but certainly more noticeable because I have more time to notice and at times ruminate and obsess about it. By the way, the meds. help with the coping with the VS.

What is strange about VS looking back is that there were long periods throughout the years, months at a time when I wouldn?t even notice it or have any issue.

The revelation came when two months ago, I just happened to Google search the symptom ?twinkling?, anxiety symptoms related to the eye. I came across the EOV website and others and discovered I wasn?t alone (aka ?nuts?) and there is are others with the VS that I had.? I?m not alone!!!! I was ecstatic after all these years!!! I burnt out my printer. Killed lots of trees printing a manual on VS and floaters. Thank God for the internet.

Then the somewhat sobering news that there is little known about it, cause and treatment, as well as some medications that have been tried. Very empirical treatments to say the least.

I am going to pursue further diagnostics at this age to see if there are any experimental medications I could try. Emory Eye Center, Bascom Palmer, what doctor I am not sure. Either way, I can live with VS but want to explore. Wouldn?t it be something if I could see without the full vision of PMA, VS and floaters. I hope I could handle it. I can.

Rick Rakusin


 
Stem cell treatment for Macular Degeneration in Germany

Macular degeneration is a retinal degenerative disease that causes progressive loss of central vision. The risk of developing Macular degeneration increases with age. The disease most often affects people in their sixties and seventies........

 

PRLog (Press Release) ? Apr 29, 2010 ? Macular degeneration is a retinal degenerative disease that causes progressive loss of central vision. The risk of developing Macular degeneration increases with age. The disease most often affects people in their sixties and seventies. Macular degeneration is the most common cause of vision loss in individuals over the age of fifty.
Now a day?s treating incurable diseases is not a major issue, Stem Cell Therapy has helped many patients getting treatment for incurable diseases of which Macular Degeneration is one disease.

SCGF center in Germany is one such center known for providing the stem cell treatments to the needy patients suffering from macular degeneration following the proper ethical standards. The stem cells are first collected from a patient's bone marrow, extracted from the hipbone (iliac crest) then re-injected; stem cells have the potential to transform into multiple types of cells and are capable of regenerating damaged tissue. Our innovative stem cell treatments use the self-healing potential of each patient's own body to stimulate regeneration or repair.

Here is the case of one female patient, 45 years of age who got her treatment from one of the SCGF center in Germany. In the past, this patient had undergone several photodynamic laser macula treatments and two "lucentis" intra vitreo injections with a disastrous clinical result. Her clinical condition continued to worsen.

At last she finds her way to SCGF center in Germany and when she arrived at the center in for the first time, she had a central scotoma on the left eye and she was not able to count her fingers. In the right eye the experts observed the onset of macula degeneration with macula epiteliopathy and 9/10 corrected visual acuity that have been able to preserve until the present.

After some detoxification treatments the patient was sent to the center for a bilateral autologous stem cell retro-bulbar implantation. Just two weeks after the treatment, during an objective, standardized examination, this patient showed significant improvement.
As per the experts the retro-bulbar injection of autologous stem cells might first prevent the progression of dry and wet macular degeneration by reducing the Drusen deposits in the retinal pigment epithelium beneath the macula. It also prevents the destruction of the photoreceptors in both the dry and wet type, by reactivating proper micro-vessel activity and reducing the abnormal blood vessel growth beneath.

SCGF Center operates treatment centers in Cologne and D?sseldorf, Germany. It is the first privately-owned clinic in Europe to specialize in regenerative medicine using autologous bone marrow stem cell therapy and operates in accordance with German law and European guidelines. Its specialized medical team of German physicians includes specialists in: neurosurgery, orthopedics, cardiology, radiology, anesthesiology and pharmacology.

?As global stem cells market is seen to have such a big projection in the coming years we don?t want to leave behind in providing Stem Cell Therapy and Cord blood transplants to the needy ones giving smiles on their faces? says, Mr. Karan Goel, Chairman, Stem Cell Global Foundation


Source:

Stem Cell Global Foundation
www.stemcellgf.org
Tel: +44-203-004-9359
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 
<< Start < Prev 21 22 23 24 25 26 27 28 29 Next > End >>

Page 23 of 29